Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25092562 | 0.77 | HDAC6 (0.39) | CREBBPHSP90AA1HSP90AB1RPS6KA3 | |
| SCHEMBL22214097 | 0.77 | ERCC1 (0.40) | HSP90AA1HSP90AB1HTR3A | |
| SCHEMBL24924342 | 0.75 | BRD4 (0.40) | CREBBPHSP90AA1HSP90AB1BMPR1BBMPR1A | |
| SCHEMBL25065216 | 0.72 | CYP11B1 (0.39) | HSP90AA1HSP90AB1RPS6KA3 | |
| SCHEMBL22313085 | 0.72 | NPC1 (0.33) | FFAR1 | |
| SCHEMBL25092431 | 0.70 | ROCK2 (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL22312941 | 0.69 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1RPS6KA3ACLY | |
| SCHEMBL25065222 | 0.68 | NOTUM (0.38) | HSP90AA1RPS6KA3 | |
| SCHEMBL17806580 | 0.66 | IDH1 (0.45) | CREBBPFFAR1IDH1 | |
| SCHEMBL23434932 | 0.65 | LMNA (0.48) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CREBBP 475/4885HSP90AA1 2130/4885HSP90AB1 1650/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CREBBP 380/4885HSP90AA1 2009/4885HSP90AB1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.